AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16187913 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAb levels in relapse group (11.1 IU/L ± 0.17)
Number of subjects: 96
Study 16187913 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAb cutoff value of 1.5 IU/L
Number of subjects: 96
Study 16187913 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAb cutoff level of 10 IU/L
Number of subjects: 96
Study 12362932 — intervention group
Group type: EXPERIMENTAL
Intervention: Seville orange juice
Number of subjects: 13
Study 12362932 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 13
Study 12362932 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 13
Study 9854661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 20
Study 9854661 — intervention group
Group type: COMPARATOR
Intervention: Iloprost
Number of subjects: 20
Study 7787129 — intervention group
Group type: EXPERIMENTAL
Intervention: saline‐polyethylene glycol solution (SPG)
Number of subjects: 12
Study 7787129 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 2079572 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 megaunits of recombinant interferon alfa‐2b (INTRON A, R Schering‐Plough, Essex Corporation) subcutaneously thrice weekly for 4 months
Number of subjects: 58
Study 2079572 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 58
Study 341941 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 18
Study 341941 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 18
Study 341941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31298217 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical and tailored text-based feedback with PROMs
Number of subjects: 1386
Study 31298217 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical feedback only
Number of subjects: 1386
Study 31298217 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical feedback
Number of subjects: 1386
Study 31298217 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based feedback
Number of subjects: 1386
Study 31298217 — intervention group
Group type: COMPARATOR
Intervention: WHOQOL-CAT
Number of subjects: 1386
Study 28545195 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire assessing knowledge and screening compliance
Number of subjects: 506
Study 28545195 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban residence
Number of subjects: 506
Study 28545195 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of risk factors
Number of subjects: 506
Study 28545195 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal fears (of screening being embarrassing)
Number of subjects: 506
Study 25714882 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (3 g/daily)
Number of subjects: 12
Study 25714882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23949026 — intervention group
Group type: EXPERIMENTAL
Intervention: Premotor Therapy
Number of subjects: 15
Study 23949026 — intervention group
Group type: COMPARATOR
Intervention: Motor Therapy
Number of subjects: 15
Study 21570514 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 973
Study 21570514 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARBs
Number of subjects: 973
Study 21570514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering medications (LL)
Number of subjects: 973
Study 19539105 — intervention group
Group type: EXPERIMENTAL
Intervention: Aropotin (albumin-free rhEPO) 50 IU/kg
Number of subjects: 12
Study 19539105 — intervention group
Group type: EXPERIMENTAL
Intervention: Aropotin (albumin-free rhEPO) 100 IU/kg
Number of subjects: 12
Study 19539105 — intervention group
Group type: COMPARATOR
Intervention: Recormon 100 IU/kg
Number of subjects: 12
Study 19539105 — intervention group
Group type: COMPARATOR
Intervention: Espogen 100 IU/kg
Number of subjects: 12
Study 19539105 — intervention group
Group type: COMPARATOR
Intervention: Aropotin 100 IU/kg
Number of subjects: 12
Study 16934438 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei A (100 g/day of fermented milk)
Number of subjects: 26
Study 12174920 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg
Number of subjects: 0
Study 12174920 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/day
Number of subjects: 0
Study 12174920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10201714 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Number of subjects: 67
Study 10201714 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam hydrochloride
Number of subjects: 67
Study 10201714 — intervention group
Group type: COMPARATOR
Intervention: 10% dextrose (placebo)
Number of subjects: 67
Study 8592284 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical butamben picrate
Number of subjects: 0
Study 2348383 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 6
Study 2348383 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 40709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg single dose)
Number of subjects: 26
Study 40709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg twice daily for 4 weeks)
Number of subjects: 26
Study 40709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31657646 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment
Number of subjects: 0
Study 31657646 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal from methylphenidate treatment
Number of subjects: 0
Study 29357480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant human EPO (5,000 IU) over 4 weeks (n = 12)
Number of subjects: 24
Study 29357480 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose recombinant human EPO (500 IU·kg body wt‐1·day‐1 for three consecutive days) (n = 12)
Number of subjects: 24
Study 29357480 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 24
Study 27075185 — intervention group
Group type: EXPERIMENTAL
Intervention: Embodied training using a randomized crossover design to divide a presented line into equal segments by walking with equally spaced steps.
Number of subjects: 0
Study 27075185 — intervention group
Group type: COMPARATOR
Intervention: Control training with no involvement of task-specific whole-body movements.
Number of subjects: 0
Study 25670222 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol
Number of subjects: 137
Study 25670222 — intervention group
Group type: EXPERIMENTAL
Intervention: D-chiro inositol
Number of subjects: 137
Study 25670222 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 137
Study 22994682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 243
Study 22994682 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 243
Study 22994682 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both drugs (NAC and ascorbic acid)
Number of subjects: 243
Study 22994682 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline hydration alone)
Number of subjects: 243
Study 20605202 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (2 mg) and metformin (500 mg) twice daily
Number of subjects: 207
Study 20605202 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 207
Study 20605202 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone and metformin
Number of subjects: 207
Study 18687512 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice advisory manikin (VAM) training
Number of subjects: 43
Study 18687512 — intervention group
Group type: COMPARATOR
Intervention: Instructor facilitated (IF) training
Number of subjects: 43
Study 16962381 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with antiretroviral therapy
Number of subjects: 0
Study 16962381 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no early treatment)
Number of subjects: 0
Study 12866252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (n = 54)
Number of subjects: 412
Study 12866252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 12866252 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression screening using SCL-90, Zung, BDI, and HADS
Number of subjects: 412
Study 12866252 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety
Number of subjects: 412
Study 9527302 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice intervention trials
Number of subjects: 0
Study 9527302 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary measures for each practice
Number of subjects: 0
Study 7542707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation or fortification
Number of subjects: 0
Study 7542707 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplementation or fortification
Number of subjects: 0
Study 7542707 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation trials and programs for dietary diversity and quality
Number of subjects: 0
Study 2224785 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-ethyl-10-deaza-aminopterin (10-EdAM)
Number of subjects: 9
Study 2224785 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 9
Study 359772 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate treatment
Number of subjects: 12
Study 359772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31288233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab intravenous infusion followed by subcutaneous maintenance dose of 90 mg every 8 weeks
Number of subjects: 14
Study 30957594 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass azithromycin distribution
Number of subjects: 24
Study 27622854 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise during pregnancy
Number of subjects: 18
Study 27622854 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (inactive during pregnancy)
Number of subjects: 18
Study 25234471 — intervention group
Group type: COMPARATOR
Intervention: Blood Cu/Zn ratio in ASD group
Number of subjects: 52
Study 25234471 — intervention group
Group type: COMPARATOR
Intervention: Blood levels of metals (Zn, Cu, Al, Pb, Hg)
Number of subjects: 52
Study 25234471 — intervention group
Group type: COMPARATOR
Intervention: Uroporphyrin I, heptacarboxyporphyrin I, hexacarboxyporphyrin, pentacarboxyporphyrin I
Number of subjects: 52
Study 25234471 — intervention group
Group type: COMPARATOR
Intervention: Coproporphyrin I and coproporphyrin III levels
Number of subjects: 52
Study 24479722 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 20 mg methylprednisolone
Number of subjects: 50
Study 24479722 — intervention group
Group type: COMPARATOR
Intervention: Topical steroid eye drops (dexamethasone 1 mg/ml)
Number of subjects: 50
Study 23040644 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Focus
Number of subjects: 128
Study 23040644 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 128
Study 19398384 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-based acceptance intervention with values component (n = 34)
Number of subjects: 99
Study 19398384 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-based acceptance intervention without values component (n = 30)
Number of subjects: 99
Study 19398384 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 35)
Number of subjects: 99
Study 18090079 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 122
Study 18090079 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 122
Study 15138657 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of hospital stay (Group A)
Number of subjects: 238
Study 15138657 — intervention group
Group type: COMPARATOR
Intervention: More than 2 days of hospital stay (Group B)
Number of subjects: 238
Study 12487842 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based practice (EBP)
Number of subjects: 0
Study 12487842 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trials (RCTs)
Number of subjects: 0
Study 12487842 — intervention group
Group type: COMPARATOR
Intervention: Guidelines and protocols
Number of subjects: 0
Study 12487842 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational initiatives and organisational commitment
Number of subjects: 0
Study 9822097 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 110
Study 9822097 — intervention group
Group type: COMPARATOR
Intervention: Accelerated rt-PA
Number of subjects: 110
Study 7662247 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (quinapril or captopril); duration: 6 months
Number of subjects: 39
Study 7662247 — intervention group
Group type: COMPARATOR
Intervention: Baseline placebo period
Number of subjects: 39
Study 7662247 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (quinapril or captopril)
Number of subjects: 39
Study 29288055 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin + Ticagrelor
Number of subjects: 32
Study 29288055 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 32
Study 29288055 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 32
Study 27212277 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg five times daily for one week)
Number of subjects: 27
Study 27212277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 25377520 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing medical education (CME) on early cancer diagnosis targeting individual GPs.
Number of subjects: 836
Study 25377520 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 836
Study 23558303 — intervention group
Group type: EXPERIMENTAL
Intervention: High fluid management (8 mL/[kg · h])
Number of subjects: 102
Study 23558303 — intervention group
Group type: COMPARATOR
Intervention: Low fluid management (2 mL/[kg · h])
Number of subjects: 102
Study 20854384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon (2g daily for 12 weeks)
Number of subjects: 58
Study 20854384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 19114297 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal midazolam (0.2mg/kg)
Number of subjects: 120
Study 19114297 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (0.3mg/kg)
Number of subjects: 120
Study 16633152 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Number of subjects: 20
Study 16633152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15317709 — intervention group
Group type: EXPERIMENTAL
Intervention: Foldable multifocal intraocular lenses (IOLs)
Number of subjects: 190
Study 15317709 — intervention group
Group type: COMPARATOR
Intervention: Foldable monofocal intraocular lenses (IOLs)
Number of subjects: 190
Study 10825320 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg dolasetron IV
Number of subjects: 200
Study 10825320 — intervention group
Group type: COMPARATOR
Intervention: 25 mg dolasetron IV
Number of subjects: 200
Study 10825320 — intervention group
Group type: COMPARATOR
Intervention: 4 mg ondansetron IV
Number of subjects: 200
Study 10825320 — intervention group
Group type: COMPARATOR
Intervention: 8 mg ondansetron IV
Number of subjects: 200
Study 9288632 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinoma in situ (10 patients)
Number of subjects: 30
Study 9288632 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive epidermoid carcinoma (20 patients)
Number of subjects: 30
Study 8306572 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural IFN alpha for 12 months
Number of subjects: 64
Study 8306572 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IFN alpha 2b for 12 months
Number of subjects: 64
Study 8306572 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural IFN alpha for 6 months
Number of subjects: 64
Study 8306572 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IFN alpha 2b for 6 months
Number of subjects: 64
Study 8306572 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural IFN alpha for 3 months
Number of subjects: 64
Study 8306572 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IFN alpha 2b for 3 months
Number of subjects: 64
Study 3716654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy
Number of subjects: 30
Study 3716654 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued group therapy
Number of subjects: 30
Study 3716654 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy (completed treatment)
Number of subjects: 30
Study 3716654 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard psychoanalytic therapy
Number of subjects: 30
Study 3716654 — intervention group
Group type: COMPARATOR
Intervention: Control group (discontinued group therapy)
Number of subjects: 30
Study 3716654 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall therapy
Number of subjects: 30
Study 3716654 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly selected group of patients (1977)
Number of subjects: 30
Study 30646650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention in addition to routine treatment and respiratory function exercise
Number of subjects: 60
Study 30646650 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment and respiratory function exercise
Number of subjects: 60
Study 27698630 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynasplint stretching (experimental group)
Number of subjects: 50
Study 27698630 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory medication plus instructions on daily home stretching (control group)
Number of subjects: 50
Study 23893252 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mental health care (EMH)
Number of subjects: 1170
Study 23893252 — intervention group
Group type: COMPARATOR
Intervention: occupational physician care (OP)
Number of subjects: 1170
Study 22326506 — intervention group
Group type: EXPERIMENTAL
Intervention: High confederate intake
Number of subjects: 223
Study 22326506 — intervention group
Group type: EXPERIMENTAL
Intervention: Low confederate intake
Number of subjects: 223
Study 22326506 — intervention group
Group type: EXPERIMENTAL
Intervention: No confederate intake
Number of subjects: 223
Study 19772940 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 811
Study 19772940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 811
Study 19772940 — intervention group
Group type: COMPARATOR
Intervention: Baseline characteristics comparison
Number of subjects: 811
Study 18310232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexus coils
Number of subjects: 101
Study 18310232 — intervention group
Group type: COMPARATOR
Intervention: GDC 10 coils
Number of subjects: 101
Study 18310232 — intervention group
Group type: COMPARATOR
Intervention: Trufill coils
Number of subjects: 101
Study 15793788 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE D allele prevalence in SI group
Number of subjects: 108
Study 15793788 — intervention group
Group type: EXPERIMENTAL
Intervention: DD genotype group
Number of subjects: 108
Study 15793788 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 108
Study 12425139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully digital hearing aid (DigiFocus compact/Oticon)
Number of subjects: 17
Study 12425139 — intervention group
Group type: COMPARATOR
Intervention: Analog digitally programmable two-channel hearing aid
Number of subjects: 17
Study 12425139 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual hearing aid
Number of subjects: 17
Study 10367222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patch (10 mg/24 h) administered four hours before tests in the acute phase.
Number of subjects: 11
Study 10367222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patch (10 mg/24 h) administered continuously for 25 days in the chronic phase.
Number of subjects: 11
Study 10367222 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-dipyridamole test after chronic therapy (Dip 2).
Number of subjects: 11
Study 7738625 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens based on platinum derivatives
Number of subjects: 1052
Study 7738625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression model and RECPAM analysis
Number of subjects: 1052
Study 7738625 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil count
Number of subjects: 1052
Study 1799916 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim 200 mg once daily for 7-10 days
Number of subjects: 80
Study 1799916 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 750 mg thrice daily for 7-10 days
Number of subjects: 80
Study 1799916 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim
Number of subjects: 80
Study 1799916 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 80
Study 7471129 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg clotrimazole vaginal tablet daily for seven days (group I)
Number of subjects: 54
Study 7471129 — intervention group
Group type: COMPARATOR
Intervention: Two 100 mg clotrimazole vaginal tablets daily for three days (group II)
Number of subjects: 54
Study 31789307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-modality therapy
Number of subjects: 893
Study 28630863 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin at a dose of 2×5 mg with atorvastatin or rosuvastatin at a standardized daily dose of 20 mg
Number of subjects: 60
Study 28630863 — intervention group
Group type: COMPARATOR
Intervention: Placebo with atorvastatin or rosuvastatin at a standardized daily dose of 20 mg
Number of subjects: 60
Study 26730752 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic tracheotomy
Number of subjects: 39
Study 26730752 — intervention group
Group type: COMPARATOR
Intervention: Control (no tracheotomy)
Number of subjects: 39